Application of MT-ND6 as new target in metabolic syndrome diagnosis and treatment drugs
A MT-ND6, 1. MT-ND6 technology is applied in the fields of biology and medicine, achieving good application prospects, important development value, and easy operation
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0050] The methylation of MT-ND6 gene can be used as a biomarker for early clinical screening, diagnosis and prognosis of insulin resistance-based metabolic syndrome such as obesity, type 2 diabetes and its complications
[0051] Such as figure 1 As shown in A and C, the methylation level of MT-ND6 gene was significantly increased in the peripheral blood leukocytes of type 2 diabetics and the liver of obese mice. Such as figure 2 As shown in C and D, linear correlation analysis showed that the methylation level of MT-ND6 gene in human peripheral blood leukocytes was positively correlated with the content of HOMA-IR and glycosylated hemoglobin, suggesting that methylation of MT-ND6 could be used as a biomarker of insulin resistance thing. Since insulin resistance is the pathological basis and core link of many metabolic diseases such as obesity and type 2 diabetes, the methylation of MT-ND6 gene can be used as an early clinical screening for metabolic syndrome and its compli...
Embodiment 2
[0053] Methylation of MT-ND6 gene can be used as a biomarker for early clinical screening, diagnosis and prognosis of hyperlipidemia (or hyperlipidemia)
[0054] Elevated triglyceride content in serum is one of the most important features of hyperlipidemia (or hyperlipidemia), such as figure 2 As shown in B, the methylation modification level of the MT-ND6 gene in human peripheral blood leukocytes is linearly positively correlated with the serum triglyceride level, suggesting that the methylation of the MT-ND6 gene can be a symptom of hyperlipidemia (or hyperlipidemia) Biomarkers for early clinical screening, diagnosis and prognosis.
Embodiment 3
[0056] The expression level of MT-ND6 can be used as a biomarker for early clinical screening, diagnosis and prognosis of hyperlipidemia (or hyperlipidemia), obesity, type 2 diabetes and metabolic syndrome and its complications
[0057] Such as figure 1 As shown in B and D, the mRNA expression level of MT-ND6 gene was decreased in type 2 diabetic humans and obese mice, and at the same time as figure 2 As shown in A, the methylation of MT-ND6 gene in human peripheral blood leukocytes is linearly negatively correlated with its mRNA expression. Since the methylation level of MT-ND6 was linearly positively correlated with serum triglyceride, HOMA-IR and glycosylated hemoglobin ( figure 2 B-D), it can be seen that the mRNA expression of MT-ND6 gene is linearly and negatively correlated with serum triglyceride, HOMA-IR and glycosylated hemoglobin content, suggesting that the expression level of MT-ND6 (mRNA and protein level) can be used as a sign of hyperlipidemia (or hyperlipid...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com